PL3233862T3 - Pochodne imidazopirydazyny jako inhibitory PI3Kbeta - Google Patents

Pochodne imidazopirydazyny jako inhibitory PI3Kbeta

Info

Publication number
PL3233862T3
PL3233862T3 PL15810784T PL15810784T PL3233862T3 PL 3233862 T3 PL3233862 T3 PL 3233862T3 PL 15810784 T PL15810784 T PL 15810784T PL 15810784 T PL15810784 T PL 15810784T PL 3233862 T3 PL3233862 T3 PL 3233862T3
Authority
PL
Poland
Prior art keywords
pi3kbeta
inhibitors
imidazopyridazine derivatives
imidazopyridazine
derivatives
Prior art date
Application number
PL15810784T
Other languages
English (en)
Inventor
Laurence Anne Mevellec
Lieven Meerpoel
Sophie Coupa
Virginie Sophie Poncelet
Isabelle Noëlle Constance PILATTE
Elisabeth Thérèse Jeanne PASQUIER
Didier Jean-Claude Berthelot
Olivier Alexis Georges Querolle
Christophe Meyer
Patrick René Angibaud
Christophe Gabriel Marcel Demestre
Guillaume Jean Maurice Mercey
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PL3233862T3 publication Critical patent/PL3233862T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL15810784T 2014-12-19 2015-12-18 Pochodne imidazopirydazyny jako inhibitory PI3Kbeta PL3233862T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14199322 2014-12-19
PCT/EP2015/080604 WO2016097347A1 (en) 2014-12-19 2015-12-18 IMIDAZOPYRIDAZINE DERIVATIVES AS ΡΙ3Κβ INHIBITORS
EP15810784.7A EP3233862B1 (en) 2014-12-19 2015-12-18 Imidazopyridazine derivatives as pi3kbeta inhibitors

Publications (1)

Publication Number Publication Date
PL3233862T3 true PL3233862T3 (pl) 2020-01-31

Family

ID=52134002

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15810784T PL3233862T3 (pl) 2014-12-19 2015-12-18 Pochodne imidazopirydazyny jako inhibitory PI3Kbeta

Country Status (25)

Country Link
US (1) US10087187B2 (pl)
EP (1) EP3233862B1 (pl)
JP (1) JP6568588B2 (pl)
KR (1) KR20170095239A (pl)
CN (1) CN107108634B (pl)
AU (1) AU2015366190B2 (pl)
BR (1) BR112017012930A2 (pl)
CA (1) CA2967551A1 (pl)
CY (1) CY1122381T1 (pl)
DK (1) DK3233862T3 (pl)
EA (1) EA029789B1 (pl)
ES (1) ES2761051T3 (pl)
HR (1) HRP20191550T1 (pl)
HU (1) HUE045220T2 (pl)
IL (1) IL252866B (pl)
LT (1) LT3233862T (pl)
MA (1) MA41174B1 (pl)
MD (1) MD3233862T2 (pl)
ME (1) ME03517B (pl)
MX (1) MX2017008074A (pl)
PL (1) PL3233862T3 (pl)
PT (1) PT3233862T (pl)
RS (1) RS59301B1 (pl)
SI (1) SI3233862T1 (pl)
WO (1) WO2016097347A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017060406A1 (en) 2015-10-09 2017-04-13 Janssen Pharmaceutica Nv Quinoxaline and pyridopyrazine derivatives as pi3kbeta inhibitors
KR102472453B1 (ko) 2016-06-16 2022-11-29 얀센 파마슈티카 엔.브이. Pi3k 베타 저해제로서의 이환식 피리딘, 피라진, 및 피리미딘 유도체
KR20190133729A (ko) 2017-03-29 2019-12-03 얀센 파마슈티카 엔.브이. Pi3k-베타 억제제로서 퀴녹살린 및 피리도피라진 유도체
CN110128505A (zh) * 2019-05-21 2019-08-16 梯尔希（南京）药物研发有限公司 一种戈舍瑞林杂质的合成方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
EP2046333A4 (en) 2006-07-24 2010-09-15 Glaxosmithkline Llc THIOZOLIDINEDIONE DERIVATIVES AS INHIBITORS OF P13-KINASE
WO2008030579A2 (en) 2006-09-07 2008-03-13 Biogen Idec Ma Inc. Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder
WO2008138834A1 (en) * 2007-05-09 2008-11-20 Novartis Ag Substituted imidazopyridazines as pi3k lipid kinase inhibitors
WO2009060197A1 (en) * 2007-11-08 2009-05-14 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazopyridazines for use as protein kinase inhibitors
PE20091468A1 (es) * 2008-02-28 2009-10-22 Novartis Ag DERIVADOS DE 3-METIL-IMIDAZO-[1,2-b]-PIRIDAZINA
WO2010007099A1 (en) 2008-07-15 2010-01-21 Cellzome Limited 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors
GEP201706639B (en) 2009-08-17 2017-03-27 Intellikine Llc Heterocyclic compounds and uses thereof
DE102009049679A1 (de) 2009-10-19 2011-04-21 Merck Patent Gmbh Pyrazolopyrimidinderivate
WO2011058109A1 (en) 2009-11-12 2011-05-19 Ucb Pharma S.A. Fused bicyclic pyrrole and imidazole derivatives as kinase inhibitors
UY33304A (es) 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
NZ608069A (en) 2010-10-06 2014-06-27 Glaxosmithkline Llc Benzimidazole derivatives as pi3 kinase inhibitors
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
US9096605B2 (en) * 2011-08-24 2015-08-04 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as PI3 kinase inhibitors
US8778937B2 (en) 2011-12-20 2014-07-15 Glaxosmithkline Llc Benzimidazole boronic acid derivatives as PI3 kinase inhibitors
WO2013095761A1 (en) 2011-12-20 2013-06-27 Glaxosmithkline Llc Imidazopyridine derivatives as pi3 kinase inhibitors
TWI574962B (zh) 2012-11-14 2017-03-21 加拓科學公司 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途
GB201321734D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents

Also Published As

Publication number Publication date
LT3233862T (lt) 2019-09-10
KR20170095239A (ko) 2017-08-22
BR112017012930A2 (pt) 2018-01-09
WO2016097347A1 (en) 2016-06-23
MD3233862T2 (ro) 2019-11-30
EP3233862B1 (en) 2019-07-03
CN107108634B (zh) 2020-09-15
RS59301B1 (sr) 2019-10-31
ME03517B (me) 2020-04-20
JP6568588B2 (ja) 2019-08-28
ES2761051T3 (es) 2020-05-18
SI3233862T1 (sl) 2019-09-30
MA41174B1 (fr) 2019-09-30
US20180002336A1 (en) 2018-01-04
IL252866B (en) 2020-09-30
JP2017538734A (ja) 2017-12-28
EA029789B1 (ru) 2018-05-31
AU2015366190B2 (en) 2020-01-23
CN107108634A (zh) 2017-08-29
HRP20191550T1 (hr) 2019-11-29
IL252866A0 (en) 2017-08-31
MX2017008074A (es) 2018-01-09
DK3233862T3 (da) 2019-10-07
EP3233862A1 (en) 2017-10-25
CY1122381T1 (el) 2021-01-27
EA201791396A1 (ru) 2017-10-31
US10087187B2 (en) 2018-10-02
HUE045220T2 (hu) 2019-12-30
CA2967551A1 (en) 2016-06-23
AU2015366190A1 (en) 2017-05-25
PT3233862T (pt) 2019-10-09
MA41174A (fr) 2017-10-25

Similar Documents

Publication Publication Date Title
IL287113A (en) smyd inhibitors
IL246785A0 (en) Benzimidazole-2-amines as midh1 inhibitors
IL251420A0 (en) Triazolopyrazinones as pde1 inhibitors
HK1226398A1 (zh) 作為midh1抑制劑的苯並咪唑-2-胺
IL251932B (en) Benzylpropargyl ether as nitrification inhibitors
SG11201610904UA (en) Syk inhibitors
IL248895A0 (en) Phosphatidylinositol 3-kinase inhibitors
PT3131898T (pt) Derivados de fluoroalquilfluoreno
PL3418273T3 (pl) Pochodne flawaglin
IL248773A0 (en) History of naphthyridinedione
IL248629B (en) Substances containing diheteroaryl conjugated to cycloalkyl and their uses
IL252866B (en) History of imidazopyridazine as pi3k beta inhibitors
PL3119744T3 (pl) Pochodne 2-cyjano-3-cyklopropylo-3-hydroksy-N-arylo-tioakryloamidu
IL252868A0 (en) History of heterocyclyl-related imidazopyridazines as pi3kbeta inhibitors
HK1232214A1 (zh) 作為 抑制劑的六氫呋喃並吡咯
GB201418154D0 (en) Inhibitors